PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.06
0.06 - 0.24
8.7K / 3.59M (Avg.)
-1.55 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
73317.96%
10Y CAGR of 73317.96% while CRN.AX is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
73317.96%
Positive 5Y CAGR while CRN.AX is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
28.58%
OCF/share CAGR of 28.58% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
28.58%
Positive OCF/share growth while CRN.AX is negative. John Neff might see a comparative advantage in operational cash viability.
-171.61%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
181.61%
10Y net income/share CAGR of 181.61% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
181.61%
Positive 5Y CAGR while CRN.AX is negative. John Neff might view this as a strong mid-term relative advantage.
29.82%
Positive short-term CAGR while CRN.AX is negative. John Neff would see a clear advantage in near-term profit trajectory.
-103.58%
Negative equity/share CAGR over 10 years while CRN.AX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-103.58%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-104.87%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.